Welcome to our dedicated page for PIERIS PHARMACEUTICALS news (Ticker: PIRS), a resource for investors and traders seeking the latest updates and insights on PIERIS PHARMACEUTICALS stock.
Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) is a clinical-stage biotechnology company dedicated to developing novel Anticalin-based drugs. These drugs target specific disease pathways in innovative and transformative ways. The company's proprietary Anticalin proteins are engineered versions of human lipocalins, which naturally bind, store, and transport a wide range of molecules. This unique technology has been validated through clinical trials and partnerships with leading pharmaceutical companies.
Core Business and Products
Pieris specializes in creating a diverse pipeline of Anticalin-based therapeutics. Their current focus areas include:
- Immuno-Oncology: Multi-specifics tailored for the tumor micro-environment, such as PRS-344 targeting PD-L1 and 4-1BB, PRS-346 targeting CD228 and 4-1BB, and PRS-342 targeting GPC3 and 4-1BB.
- Respiratory Diseases: Inhaled Anticalin proteins to treat conditions like uncontrolled asthma, with ongoing projects such as elarekibep, an inhaled IL-4 receptor alpha inhibitor.
- Other Conditions: Including treatment for anemia through half-life-optimized Anticalin proteins.
Recent Achievements and Partnerships
Pieris continues to make significant strides in its research and development efforts. Despite recent setbacks such as AstraZeneca's decision to discontinue studies on elarekibep, Pieris is actively reassessing its corporate priorities and focusing on leveraging its strong partnerships with companies like Roche, Pfizer, Boston Pharmaceuticals, and Servier.
Financial Condition and Strategic Focus
As of June 30, 2023, Pieris reported cash, cash equivalents, and investments totaling approximately $54.9 million. The company has initiated a corporate restructuring to reduce workforce and operational costs, aiming to extend its cash runway. Pieris is also exploring strategic options, including new partnerships and potential acquisitions, to maximize shareholder value.
For more detailed information, visit www.pieris.com.
Pieris Pharmaceuticals (NASDAQ:PIRS) has announced an investor call on March 1, 2022, at 8:00 AM EST to discuss its 2021 financial results and provide a corporate update. Interested participants can join via phone or a webcast. A replay will be available on the company's website. Pieris specializes in developing novel biotherapeutics, including inhalable Anticalin proteins for respiratory diseases and immuno-oncology treatments, supported by their proprietary technology platform.
Pieris Pharmaceuticals (NASDAQ:PIRS) announced the dosing of the first patient in its phase 2 study of cinrebafusp alfa (PRS-343), a bispecific treatment for HER2-expressing gastric cancer. This two-arm study evaluates its efficacy, safety, and tolerability in combination with ramucirumab and paclitaxel or tucatinib. Target outcomes are an overall response rate (ORR) of at least 40% in HER2-low and 50% in HER2-high patients. The company anticipates presenting preliminary data later this year, marking a significant milestone in addressing unmet needs in gastric cancer treatment.
Pieris Pharmaceuticals (NASDAQ:PIRS) announced the successful completion of the sponsor safety review for part 1a of the phase 2a study of the drug candidate PRS-060/AZD1402, which targets moderate-to-severe asthma. This milestone allows for enrollment of part 2a, focusing on efficacy, and part 1b, assessing high-dose safety. The evaluation involved 31 patients and marked improvements in safety and pharmacokinetics. The primary endpoint for part 2a will be FEV1 improvement compared to placebo. Completion of this study is seen as a significant opportunity for the company.
Pieris Pharmaceuticals (NASDAQ:PIRS) announced participation in two upcoming investor conferences. The Jefferies London Healthcare Conference is scheduled for November 18, 2021 at 8:00 AM GMT, with a webcast available. The 4th Annual Evercore ISI HealthCONx Conference will take place on December 1, 2021 at 11:20 AM EST, also featuring a webcast. Pieris focuses on biotherapeutics for respiratory diseases and cancer through its proprietary Anticalin technology.
Pieris Pharmaceuticals has announced the first patient dosing in the phase 1/2 study of PRS-344/S095012, a bispecific targeting solid tumors. This advance triggers an undisclosed milestone payment from Servier, the company's partner in this clinical trial. PRS-344/S095012 combines 4-1BB-targeting Anticalin proteins and PD-L1-targeting antibodies, showing promising preclinical results in enhancing CD8+ T cell response and extending survival in mouse models. The open-label study will assess safety, tolerability, and anti-tumor activity in patients with advanced solid tumors.
Pieris Pharmaceuticals (PIRS) reported Q3 2021 financial results, showing a net loss of $16.5 million or $(0.24) per share, slightly improved from $(0.26) per share a year prior. The company holds over $125 million in cash, attributed to collaborations, despite rising R&D expenses totaling $18.9 million. Notably, dosing in part 1a of their phase 2a study for PRS-060/AZD1402 has been completed, with topline data expected next year. Pieris also advanced multiple studies, including cinrebafusp alfa and PRS-344. The firm announced executive promotions and partnerships with AstraZeneca, Seagen, and Genentech.
Pieris Pharmaceuticals, a clinical-stage biotechnology company, has announced it will host a third quarter 2021 investor call on November 2, 2021, at 8:00 AM EDT. The call will discuss financial results and provide a corporate update. Participants can dial 877-407-8920 (Toll Free US & Canada) or listen to the webcast. A replay will be available on the company’s website. Pieris focuses on developing Anticalin proteins for respiratory diseases and immuno-oncology, highlighting its innovative approaches in biotherapeutics.
Abcuro, Inc., a clinical-stage biotechnology company focused on therapies for autoimmune diseases and cancer, has appointed Darlene Deptula-Hicks to its Board of Directors. With over 30 years of experience in the life sciences sector, she previously served as CFO for several companies, including F-star Therapeutics (NASDAQ:FSTX) and T2 Biosystems (NASDAQ:TTOO). Her expertise in growth strategies and capital raising is expected to boost Abcuro's clinical development initiatives, particularly for its lead program, ABC008, which has received Orphan Drug Designation from the FDA.
BOSTON, MA / ACCESSWIRE / October 6, 2021 / Pieris Pharmaceuticals, a clinical-stage biotechnology company, has announced key executive promotions. Thomas Bures has been promoted to Chief Financial Officer, while Ahmed Mousa becomes Chief Business Officer. Bures, with over 20 years of finance experience, focuses on financial strategy, while Mousa will enhance business development and partnerships following his role in closing significant collaborations. The company aims to advance its immuno-oncology and inhaled biologics franchises, pushing towards transformative therapies for patients.
Pieris Pharmaceuticals (NASDAQ:PIRS) has announced management participation in two upcoming investor conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will take place on September 13, 2021, at 7:00 AM EDT. A webcast is available here. Additionally, the Cantor Global Healthcare Conference is scheduled for September 30, 2021, at 12:00 PM EDT, with a webcast accessible here. Pieris focuses on developing innovative biotherapeutics using its Anticalin technology platform.
FAQ
What is the current stock price of PIERIS PHARMACEUTICALS (PIRS)?
What is the market cap of PIERIS PHARMACEUTICALS (PIRS)?
What does Pieris Pharmaceuticals specialize in?
What are Anticalin proteins?
What is the focus of Pieris' pipeline?
What recent developments has Pieris faced?
Who are Pieris' key partners?
What is Pieris' financial strategy?
What is the status of Pieris' clinical trials?
How has Pieris responded to its recent challenges?
Where is Pieris Pharmaceuticals located?
How can investors get more information about Pieris?
